LabCorp to use more Illumina tech for diagnostic tool development; Danish team creates new pancreatic cancer test;

> As part of a new deal, LabCorp ($LH) will use a wider range of Illumina ($ILMN) next-generation gene sequencing products over the next several years to develop new diagnostic tools for a wide range of specialties. Item

> Danish scientists say they've developed a test for pancreatic cancer based on detecting microRNA molecules in whole blood. Story (reg. req.)

> Personal Genome Diagnostics in Baltimore will license technology from Johns Hopkins University that allows for improved detection of cancer mutations in circulating DNA. Item

> Researchers at the Karolinska Institutet in Sweden have found that using DNA tests for human papillomavirus allows for longer screening time between tests compared with old-fashioned cytology-based testing. Item

> A new blood test for celiac disease is designed to work in 24 hours, minus intestinal biopsies or requirements to eat gluten for a month or more. Story

Suggested Articles

InterVene secured $15 million to validate its catheter-based treatment for correcting failed one-way valves in the veins of the legs.

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.